Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
This summary details the association between AP1S1 and MEDNIK syndrome, a rare neurocutaneous and copper metabolism disorder. The body of evidence implicates AP1S1, which encodes a critical subunit of the adaptor protein 1 complex, in a spectrum of clinical findings including intellectual disability, hepatic dysfunction, and cutaneous abnormalities (PMID:23423674).
Genetic studies have identified multiple variant classes in AP1S1. Notably, a nonsense variant c.186T>G (p.Tyr62Ter) has been reported among others, and its presence has been documented in different populations, supporting a robust variant spectrum. Segregation analysis in several families has demonstrated that these variants co‐segregate with the disease phenotype (PMID:19057675).
MEDNIK syndrome follows an autosomal recessive inheritance pattern. Multiple case reports and series across diverse populations highlight not only splice‐site and frameshift mutations but also founder mutations that solidify the genetic etiology of the disorder (PMID:30244301). The recurrent findings across unrelated probands further reinforce the pathogenicity of AP1S1 alterations.
Functional assessments provide compelling support; in zebrafish models and patient fibroblasts, knockdown experiments have recapitulated the disorder’s phenotype and rescue experiments with wild‑type AP1S1 mRNA restored normal function (PMID:19057675, PMID:39269494). These studies establish a clear loss‑of‑function mechanism, confirming the role of AP1S1 in intracellular copper trafficking and homeostasis.
Integrating genetic and experimental evidence, the convergence of data from multiple studies underlines a Strong gene‑disease association. Evidence from more than four affected families, along with experimental validation of the AP1S1-mediated copper handling, supports its clinical relevance in diagnostic decision‑making and therapeutic interventions such as zinc acetate therapy.
Additional studies have broadened the phenotypic spectrum to include features like decreased circulating ceruloplasmin, intrahepatic cholestasis, peripheral neuropathy, and ichthyosis, all of which are central to the MEDNIK syndrome diagnosis. This extensive evidence base not only aids in clinical assessment but also establishes a foundation for commercial genetic testing and future research publication.
Key take‑home: Testing for AP1S1 variants is crucial in the diagnostic work‑up of MEDNIK syndrome and can directly influence treatment strategies, underscoring the importance of integrating genetic and functional evidence in patient management.
Gene–Disease AssociationStrongMultiple unrelated probands from at least 4 families exhibit segregating AP1S1 variants with consistent clinical features (PMID:19057675) and corroborative functional data (PMID:39269494). Genetic EvidenceStrongDiverse variant classes, including splice-site, nonsense, and frameshift mutations, have been reported across several studies, with recurrent founder effects supporting pathogenicity (PMID:23423674, PMID:30244301). Functional EvidenceStrongRescue experiments in zebrafish and patient fibroblasts demonstrate loss-of-function effects of AP1S1 mutations and confirm their impact on copper transporter trafficking (PMID:19057675, PMID:39269494). |